Sera Prognostics (SERA) Q1 2025 earnings summary

Executive summary

• Transitioned from clinical evidence development to commercial growth, leveraging PRIME Study and AVERT PRETERM TRIAL results to drive PreTRM adoption, with a focus on Medicaid-heavy states and targeted expansion.

• Commercial strategy centers on reimbursement, physician adoption, and formalized care recommendations, supported by pilots in key states and targeted digital campaigns.

• Strategic headcount expansion of 5–10 FTEs and board appointment of Jeff Elliott to support commercial scaling.

• Completed a $57.5 million public offering in February 2025, strengthening cash reserves to $114.2 million as of March 31, 2025.

• Sera expects continued operating losses as it invests in commercialization, clinical studies, and pipeline development, with cash runway through 2028.

Financial highlights

• Q1 2025 revenue was $38,000, up from nil in Q1 2024, with net loss at $8.2 million versus $8.1 million year-over-year.

• Operating expenses rose to $9.3 million from $9.1 million, driven by higher selling, marketing, and G&A costs.

• R&D expenses decreased by 9% to $3.3 million due to lower clinical study costs.

• Cash, cash equivalents, and marketable securities totaled $114.2 million at quarter-end, up from $68.2 million at December 31, 2024.

• Net cash used in operating activities was $7.6 million for Q1 2025; net cash provided by financing activities was $53.5 million.

Outlook and guidance

• 2025 expected to be foundational for commercialization, with focus on Medicaid pilots, expanding reimbursement, and securing payer contracts.

• PRIME Study publication progressing, with recent milestone in journal engagement; ACOG guideline inclusion could occur as early as 2027.

• Management is focused on expanding provider adoption and launching additional real-world evidence studies.